WCA recommendations for the long-term treatment of panic disorder

被引:46
作者
Pollack, MH [1 ]
Allgulander, C [1 ]
Bandelow, B [1 ]
Cassano, GB [1 ]
Greist, JH [1 ]
Hollander, E [1 ]
Nutt, DJ [1 ]
Okasha, A [1 ]
Swinson, RP [1 ]
机构
[1] Massachusetts Gen Hosp, Ctr Anxiety & Traumat Stress Related Disorders, Boston, MA 02114 USA
关键词
D O I
10.1017/S109285290000691X
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
What are the symptoms of panic disorder and how is the disorder most effectively treated? One of the most commonly encountered anxiety disorders in the primary care setting, panic disorder is a chronic and debilitating illness. The core symptoms are recurrent panic attacks coupled with anticipatory anxiety and phobic avoidance, which together impair the patient's professional, social, and familial functioning. Patients with panic disorder have medically unexplained symptoms that lead to overutilization of healthcare services. Panic disorder is often comorbid with agoraphobia and major depression, and patients may be at increased risk of cardiovascular disease and, possibly, suicide. Research into the optimal treatment of this disorder has been undertaken in the past 2 decades, and numerous randomized, controlled trials have been published. Selective serotonin reuptake inhibitors have emerged as the most favorable treatment, as they have a beneficial side-effect profile, are relatively safe (even if taken in overdose), and do not produce physical dependency. High-potency benzo-diazepines, reversible monoamine oxidase inhibitors, and tricyclic antidepressants have also shown antipanic efficacy. In addition, cognitive-behavioral therapy has demonstrated efficacy in the acute and long-term treatment of panic disorder. An integrated treatment approach that combines pharmacotherapy with cognitive-behavioral therapy may provide the best treatment. Long term efficacy and ease of use are important considerations in treatment selection, as maintenance treatment is recommended far at least 12-24 months, and in some cases, indefinitely.
引用
收藏
页码:17 / 30
页数:14
相关论文
共 141 条
[1]  
Amer Psychiat Assoc, 1998, AM J PSYCHIAT, V155, P1
[2]  
American Psychiatric Association (APA), 2013, DIAGN STAT MAN MENT, P5
[3]   EFFICACY AND SAFETY OF ALPRAZOLAM, IMIPRAMINE AND PLACEBO IN TREATING PANIC DISORDER - A SCANDINAVIAN MULTICENTER STUDY [J].
ANDERSCH, S ;
ROSENBERG, NK ;
KULLINGSJO, H ;
OTTOSSON, JO ;
BECH, P ;
BRUUNHANSEN, J ;
HANSON, L ;
LORENTZEN, K ;
MELLERGARD, M ;
RASMUSSEN, S ;
ROSENBERG, R .
ACTA PSYCHIATRICA SCANDINAVICA, 1991, 83 :18-27
[4]  
ARATO M, 2001, AM PSYCH ASS ANN M M
[5]   THE PANIC-ASSOCIATED SYMPTOM SCALE - MEASURING THE SEVERITY OF PANIC DISORDER [J].
ARGYLE, N ;
DELTITO, J ;
ALLERUP, P ;
MAIER, W ;
ALBUS, M ;
NUTZINGER, D ;
RASMUSSEN, S ;
AYUSO, JL ;
BECH, P .
ACTA PSYCHIATRICA SCANDINAVICA, 1991, 83 (01) :20-26
[6]  
ARONSON TA, 1986, AM J PSYCHIAT, V143, P643
[7]  
Bakish D, 1996, PSYCHOPHARMACOL BULL, V32, P135
[8]  
BAKISH D, 1993, CLIN NEUROPHARMACOL, V16, pS77
[9]   Paroxetine, clomipramine, and cognitive therapy in the treatment of panic disorder [J].
Bakker, A ;
van Dyck, R ;
Spinhoven, P ;
van Balkom, AJLM .
JOURNAL OF CLINICAL PSYCHIATRY, 1999, 60 (12) :831-838
[10]  
Baldwin DS, 1998, J CLIN PSYCHIAT, V59, P39